2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06B.18 Biomarker Landscape of Antibody-Drug Conjugates and Bispecific Antibodies in Clinical Trials for Lung Cancer

EP.06B.18 Biomarker Landscape of Antibody-Drug Conjugates and Bispecific Antibodies in Clinical Trials for Lung Cancer

Pdf Summary

The study examines the role of biomarkers in the clinical development of antibody-drug conjugates (ADCs) and bispecific antibodies (BsAbs) for lung cancer. Despite significant advancements in immunotherapies and targeted treatments, lung cancer remains the leading cause of cancer-related deaths globally. A crucial gap identified is the limited use of biomarker-driven approaches in developing these novel therapies.<br /><br />The research involved a thorough review of clinical trials from clinicaltrials.gov as of February 1, 2024, focusing on studies directed at non-small cell lung cancer and small cell lung cancer involving ADCs or BsAbs. Out of 95 identified trials, 47 were included in the study.<br /><br />Key findings include:<br />- Trial Phases: Majority of the trials were in early phases, with 34.04% in Phase 1 and 40.04% in Phase 1/2.<br />- Cancer Stage and Treatment Line: 95.7% targeted advanced cancer, with 85.1% focusing on second-line or later therapies.<br />- Drug Focus: BsAbs were the predominant focus in 68.1% of the trials, whereas ADCs encompassed 31.9%.<br />- Biomarker Integration: 44.7% of the trials incorporated biomarker testing, mainly utilizing NGS-based genomic subsets (59.1%) and IHC for antigen expression (40.9%).<br />- Common targets included EGFR x c-MET for BsAbs and TROP2 for ADCs. Frequent ADC payloads were MMAE (40%) and topoisomerase 1 inhibitors (26.6%).<br /><br />The study highlights a progressing trend towards biomarker-driven approaches in antibody-based lung cancer therapies, suggesting future trials should prioritize such strategies to facilitate personalized treatment methodologies. This will help enhance the precision and efficacy of lung cancer treatments.

Asset Subtitle

Madhan Srinivasan Kumar

Meta Tag

Speaker Madhan Srinivasan Kumar

Topic Pathology and Biomarkers

Keywords

biomarkers

antibody-drug conjugates

bispecific antibodies

lung cancer

clinical trials

biomarker-driven approaches

EGFR x c-MET

TROP2

NGS-based genomic subsets

personalized treatment